Biotech News

MeiraGTx Announces Oral Presentation at ObesityWeek 2026

MeiraGTx (MGTX)MeiraGTxConference / presentation

Presentation highlights the Company’s AAV-BDNF program for the treatment of severe early-onset obesity LONDON and NEW YORK, Nov. 16, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical-stage genetic medicines company, today announced the Company will

Related news

MGTXMeiraGTx2026-11-12 13:00 EST

MeiraGTx Reports Third Quarter 2026 Financial and Operational Results

CRSPCRISPR Therapeutics2026-11-10 13:30 EST

CRISPR Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference

NTLAIntellia2026-11-10 13:00 EST

Intellia Therapeutics to Present at Jefferies Global Healthcare Conference in London

CRSPCRISPR Therapeutics2026-11-09 14:16 EST

CRISPR Therapeutics Presents Phase 1b Data for CTX310® Demonstrating Reductions in ANGPTL3 and Triglycerides in Patients with Severe Hypertriglyceridemia at the American Heart Association (AHA) Scientific Sessions 2026

BCRXBioCryst Pharmaceuticals2026-11-04 21:01 EST

BioCryst to Present at Upcoming Investor Conferences

CRBUCaribou2026-11-04 14:00 EST

Caribou Biosciences Announces Presentations at the 2026 American Society of Hematology (ASH) Annual Meeting

VYGRVoyager Therapeutics2026-10-27 12:01 EST

Voyager’s Tau-Targeted Gene Therapy VY1706 and Anti-Tau Antibody VY7523 for Alzheimer’s Disease to Be Featured in Poster Presentations at CTAD 2026

MGTXMeiraGTx2026-10-27 12:00 EST

MeiraGTx Announces Four Posters at the European Society of Gene and Cell Therapy (ESGCT) 2026 Annual Congress and the Network of Excellence for ALS (NEALS) Annual Meeting

RCKTRocket Pharmaceuticals2026-10-15 11:00 EST

Rocket Pharmaceuticals to Participate in Chardan’s 10th Annual Healthcare Conference

TARAProtara Therapeutics2026-09-08 20:05 EST

Protara Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference

MeiraGTx

Genetic Medicines Company MeiraGTx develops and manufactures gene therapies for inherited retinal disease, salivary-gland disorders, and other conditions. Its vertically integrated model spans vector design, clinical development, and commercial manufacturing. Bota-Vec Botaretigene sparoparvovec is an AAV gene therapy for X-linked...

Recent company news

Stock data

Close
8.14 USD
Market cap
855.71M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States